Tradestie Institutional Equity Comparison Engine

ICU vs STLN โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ICU Overall Edge

ICU Captures Institutional Edge (2โ€“1 Pillars ยท 7โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to SeaStar Medical Holding Corporation Common Stock (ICU) driven by superior Growth & Margin, Momentum & Technical while STLN counters with relative strength in Options & Structure. Fundamentally, ICU trades at N/M Forward P/E with -816.6% operating margin (+82.0% YoY revenue) versus STLN at N/M Forward P/E and N/A operating margin (N/A YoY). In options structure, ICU sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro) against STLN sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
ICU N/M vs STLN N/M Fwd P/E
Growth & Margin Winner ICU
Op Margin -816.6% vs N/A ยท YoY +82.0% vs N/A
Momentum & Technical Winner ICU
1Y +200.4% vs -42.0% ยท 52W Pos 14% vs 1%
Options & Structure Winner STLN
BREAKDOWN (N/A IV) vs UNCLASSIFIED (N/A IV)
ICU NASDAQ
SeaStar Medical Holding Corporation Common Stock
Surgical & Medical Instruments & Apparatus
$0.94
-10.95% 1D
Market Cap $5.6M
1M Return -67.19%
1Y Return +200.45%
Forward P/E N/M
Unified AI Score
49.6 / 100 HOLD
Tech 50.0 Fund 52.0 Flow 50.0 Mom 55.0
STLN US Equity
STLN
Institutional Equity
$3.00
-5.66% 1D
Market Cap N/A
1M Return -56.58%
1Y Return -41.97%
Forward P/E N/M
Unified AI Score
46.6 / 100 HOLD
Tech 45.0 Fund 46.0 Flow 50.0 Mom 55.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: ICU +200.45% STLN -41.97% Spread: +28.72 pp (STLN Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
ICU TTM Op. Margin: -816.6% STLN TTM Op. Margin: N/A
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ICU vs STLN. Trailing 12-month operating profitability (ICU -816.6% vs STLN N/A) and valuation multiples (ICU N/M vs STLN N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: ICU (7) vs STLN (1)
Institutional Metric ICU STLN Criterion Row Winner
Market Capitalization Scale $5.6M N/A Larger Scale ICU
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +82.0% N/A Higher Growth ICU
Operating Margin (TTM) Profitability -816.6% N/A Higher Margin ICU
Net Profit Margin Profitability 0.0% N/A Higher Margin ICU
Return on Equity (ROE) Capital Efficiency -356.9% N/A Higher ROE ICU
52-Week Range Position Momentum 14% ($0โ€“$5) 1% ($3โ€“$7) Stronger Trend ICU
Beta / 30D Volatility Risk Regime 1.41ฮฒ ยท 216% Vol 1.42ฮฒ ยท 175% Vol Lower Realized Risk STLN
Unified Institutional Score Composite Signal 49.6 / 100 (HOLD) 46.6 / 100 (HOLD) Higher Composite ICU

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full ICU vs STLN Buy Guide
ICU BREAKDOWN
133d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live ICU Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
STLN UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live STLN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither ICU nor STLN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.